Eculizumab



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 19.4%
Haemolytic Uraemic Syndrome 16.0%
Hypertension 15.2%
Prophylaxis 12.3%
Paroxysmal Nocturnal Haemoglobinuria 6.3%
Renal Transplant 3.7%
Routine Health Maintenance 3.7%
Depression 2.6%
Immunosuppression 2.6%
Anticoagulant Therapy 2.4%
Nausea 2.4%
Gastrooesophageal Reflux Disease 2.1%
Supplementation Therapy 1.8%
Anaemia 1.6%
Anxiety 1.6%
Pain 1.6%
Antibiotic Therapy 1.3%
Infection Prophylaxis 1.3%
Pyrexia 1.3%
Constipation 1.0%
Gastroenteritis 11.7%
Renal Impairment 11.7%
Pyrexia 10.0%
Urinary Tract Infection 10.0%
Sepsis 8.3%
Infection 6.7%
Nausea 5.0%
Pneumonia 5.0%
Pyelonephritis 5.0%
Viral Infection 5.0%
Petechiae 3.3%
Platelet Count Decreased 3.3%
Pulmonary Embolism 3.3%
Abdominal Pain 1.7%
Abdominal Pain Upper 1.7%
Abdominal Sepsis 1.7%
Abortion Induced 1.7%
Anaemia 1.7%
Cardiac Failure 1.7%
Death 1.7%
Secondary
Product Used For Unknown Indication 39.3%
Paroxysmal Nocturnal Haemoglobinuria 10.9%
Hypertension 10.4%
Anticoagulant Therapy 10.1%
Haemolytic Uraemic Syndrome 6.8%
Prophylaxis 5.0%
Convulsion 3.5%
Immunosuppression 2.0%
Infection Prophylaxis 1.5%
Aplasia Pure Red Cell 1.3%
Autoimmune Haemolytic Anaemia 1.3%
Reflux Oesophagitis 1.3%
Transplant Rejection 1.3%
Renal Transplant 1.0%
Pyrexia 0.9%
Anaemia 0.8%
Antibiotic Therapy 0.8%
Gastrooesophageal Reflux Disease 0.8%
Prophylaxis Against Transplant Rejection 0.8%
Thrombosis Prophylaxis 0.8%
Pyelonephritis 28.8%
Urinary Tract Infection 23.2%
Infection 5.6%
Multi-organ Failure 5.6%
Pyrexia 4.8%
Pancreatitis 4.0%
Abdominal Sepsis 3.2%
Drug Ineffective 3.2%
Gastroenteritis 2.4%
Laboratory Test Abnormal 2.4%
Meningitis 2.4%
Abdominal Pain 1.6%
Anaemia 1.6%
Gastrointestinal Haemorrhage 1.6%
Haemolysis 1.6%
Kidney Transplant Rejection 1.6%
Meningococcal Sepsis 1.6%
Post Procedural Haemorrhage 1.6%
Renal Impairment 1.6%
Ruptured Cerebral Aneurysm 1.6%
Concomitant
Aplastic Anaemia 26.5%
Product Used For Unknown Indication 20.6%
Bone Marrow Conditioning Regimen 14.7%
Renal Transplant 8.8%
Paroxysmal Nocturnal Haemoglobinuria 7.4%
Myelodysplastic Syndrome 5.9%
Thrombosis Prophylaxis 2.9%
Antiphospholipid Syndrome 1.5%
Aspergillus Infection 1.5%
Hypertension 1.5%
Portal Vein Thrombosis 1.5%
Prophylaxis 1.5%
Prophylaxis Against Transplant Rejection 1.5%
Pyelonephritis 1.5%
Stem Cell Transplant 1.5%
Systemic Lupus Erythematosus 1.5%
Paroxysmal Nocturnal Haemoglobinuria 18.2%
Haemolytic Uraemic Syndrome 9.1%
Spinal Deformity 9.1%
Transplant Failure 9.1%
Budd-chiari Syndrome 4.5%
Diabetes Mellitus 4.5%
Dialysis 4.5%
Dyspnoea 4.5%
Fungal Infection 4.5%
Haemolysis 4.5%
Hepatocellular Injury 4.5%
Normal Newborn 4.5%
Plasma Cell Myeloma 4.5%
Somnolence 4.5%
Vomiting 4.5%
Weight Increased 4.5%